KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) EBT (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed EBT for 17 consecutive years, with $929.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 202.23% to $929.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $995.5 million, a 142.5% increase, with the full-year FY2025 number at $995.5 million, up 142.5% from a year prior.
  • EBT was $929.2 million for Q4 2025 at Bio-Rad Laboratories, up from -$431.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $5.0 billion in Q3 2021 to a low of -$4.4 billion in Q1 2022.
  • A 5-year average of -$72.7 million and a median of $111.0 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 436.72% in 2022, then surged 528.44% in 2024.
  • Bio-Rad Laboratories' EBT stood at -$2.0 billion in 2021, then skyrocketed by 153.84% to $1.1 billion in 2022, then tumbled by 60.75% to $428.4 million in 2023, then tumbled by 312.16% to -$908.9 million in 2024, then soared by 202.23% to $929.2 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's EBT are $929.2 million (Q4 2025), -$431.1 million (Q3 2025), and $414.0 million (Q2 2025).